EDARAVONE by Hikma is 12. Approved for amyotrophic lateral sclerosis (als). First approved in 2024.
Drug data last refreshed 18h ago
12.1 Mechanism of Action The mechanism by which RADICAVA and RADICAVA ORS exert their therapeutic effect in patients with ALS is unknown. 12.2 Pharmacodynamics Cardiac Electrophysiology At exposures at least 5 times higher than that of the recommended doses of RADICAVA and RADICAVA ORS, edaravone…
Worked on EDARAVONE at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease
ASURE: Alzheimer Study Using oRal Edaravone
Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS
Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis
Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS